PharmaEssentia has reaffirmed its commitment to creating access to critical interferon therapies amid a reported global shortage. The Burlington, Massachusetts-based company noted a recent reported shortage of Pegasys (peginterferon alfa-2a). With concerns growing over drug shortages for other therapies, the company said its established cGMP manufacturing network and patient-focused approach can help it meet the…